5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Latest News

11 hours	Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution KNSA +23.48% GlobeNewswire
Apr-23	Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026 KNSA GlobeNewswire
Apr-21	Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 EXEL +5.23% Business Wire
Apr-21	Alkermes to Report First Quarter Financial Results on May 5, 2026 ALKS Business Wire
Apr-21	Why Dow Jones Stock Merck Skidded 4% - And Boosted A Key Rival EXEL +5.23% Investor's Business Daily
Apr-19	KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma IMCR GlobeNewswire
Apr-16	Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting ALKS Business Wire
Apr-14	Findings From Long-Term Analysis of the Effects of LYBALVI (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry ALKS Business Wire
Apr-13	Preparation is key to understanding global trade compliance for trials ALKS Clinical Trials Arena
Apr-08	Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST (rilonacept) in Recurrent Pericarditis KNSA GlobeNewswire
Apr-06	Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall Market KNSA Investor's Business Daily
Apr-06	Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference IMCR GlobeNewswire
Apr-01	Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 ALKS Business Wire
Mar-30	Lillys AI commitment expands through deal with Insilico EXEL BioPharma Dive
Mar-17	Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting IMCR GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)